Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Cytosorbents (CTSO) over the last 11 years, with Q3 2025 value amounting to $2.8 million.

  • Cytosorbents' Treasury Shares rose 34391.71% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 34391.71%. This contributed to the annual value of $2.8 million for FY2024, which is 55260.57% up from last year.
  • Latest data reveals that Cytosorbents reported Treasury Shares of $2.8 million as of Q3 2025, which was up 34391.71% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Treasury Shares registered a high of $2.8 million during Q3 2025, and its lowest value of $125340.0 during Q2 2022.
  • Moreover, its 5-year median value for Treasury Shares was $344247.0 (2021), whereas its average is $879376.0.
  • In the last 5 years, Cytosorbents' Treasury Shares tumbled by 6359.01% in 2022 and then surged by 55260.57% in 2024.
  • Over the past 5 years, Cytosorbents' Treasury Shares (Quarter) stood at $304962.0 in 2021, then increased by 2.34% to $312092.0 in 2022, then soared by 37.94% to $430505.0 in 2023, then surged by 552.61% to $2.8 million in 2024, then increased by 1.33% to $2.8 million in 2025.
  • Its Treasury Shares was $2.8 million in Q3 2025, compared to $2.8 million in Q2 2025 and $2.8 million in Q1 2025.